Business
aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan
aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties Kyorin to fund all ATYR1923
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties\n Kyorin to fund all ATYR1923 development and commercialization activities in Japan SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., for the development and commercialization of aTyr’s lead clinical candidate, ATYR1923, for interstitial lung diseases, or ILDs, in Japan. aTyr will receive an $8 million upfront payment and is eligible to receive up to an additional $167 million in the aggregate upon achievement of certain development, regulatory and sales milestones, as well as tiered royalties on net sales in Japan. Kyorin will receive the exclusive right to develop and commercialize ATYR1923 in Japan for ILDs. “We are very pleased to enter into this collaboration with Kyorin, a leading respiratory focused pharmaceutical company in Japan, to advance ATYR1923 in an important market,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr. “As in the U.S., ILDs represent an area of significant unmet medical need in Japan, and Kyorin’s development and commercial capabilities will enhance our ability to improve the lives of patients with these serious conditions. We believe this collaboration further validates ATYR1923 and potentially accelerates development in other ILDs.” \"We are excited to enter into this agreement with aTyr and bring this new, potentially first-in-class drug to Japanese ILD patients,\" said Yutaka Ogihara, President and Chief Executive Officer of Kyorin Holdings, Inc. Per the terms of the agreement, Kyorin will be responsible for funding all research, development, regulatory, marketing and commercialization activities in Japan. aTyr will supply all drug product for Japan, as well as support development activities as the global development leader for ATYR1923. About ATYR1923 aTyr is developing ATYR1923 as a potential therapeutic for patients with interstitial lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of h...